A Phase IB Study of Selumetinib in Patients with Inoperable or Metastatic Uveal Melanoma


Full Title

Multi-Center Phase Ib Study of Intermittent Dosing of the MEK inhibitor, Selumetinib, in Patients with advanced Uveal Melanoma Not Previously Treated with a MEK Inhibitor


Selumetinib is an investigational drug that inhibits a protein commonly involved in cancer called MEK. Prior studies evaluating its use in people with uveal melanoma (melanoma of the eye) have reported mixed results.

In this study, researchers are evaluating a new dosing schedule for selumetinib in uveal melanoma, one in which the drug is given at higher doses over a shorter time. It is hoped that this dosing schedule is more effective for blocking the molecules promoting uveal melanoma growth. Selumetinib is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have inoperable or metastatic uveal melanoma that has not previously been treated with a MEK inhibitor.
  • At least 4 weeks must pass between the completion of prior chemotherapy or immunotherapy and 2 weeks since prior radiation therapy and entry into the study.
  • Patients must be willing to undergo biopsies for research purposes.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Alexander Shoushtari at 646-888-4161.